Explore a selection of our essential drug information below, or:
Identification
- Summary
Potassium citrate is an agent used to manage renal tubular acidosis, hypocitraturic calcium oxalate nephrolithiasis, and uric acid lithiasis with or without calcium stones.
- Brand Names
- Cytra-K, Urocit-K
- Generic Name
- Potassium citrate
- DrugBank Accession Number
- DB09125
- Background
Potassium citrate (also known as tripotassium citrate) is a potassium salt of citric acid. It is a white, hygroscopic crystalline powder. It is odorless with a saline taste. It contains 38.3% potassium by mass. In the monohydrate form it is highly hygroscopic and deliquescent. Potassium citrate is used to treat a kidney stone condition called renal tubular acidosis. Potassium Citrate is indicated also for the management of Hypocitraturic calcium oxalate nephrolithiasis.
- Type
- Small Molecule
- Groups
- Approved, Investigational, Vet approved
- Structure
Structure for Potassium citrate (DB09125)
- Weight
- Average: 306.394
Monoisotopic: 305.89464697 - Chemical Formula
- C6H5K3O7
- Synonyms
- Potassium citrate anhydrous
- Tripotassium citrate
Pharmacology
- Indication
For the management of renal tubular acidosis, hypocitraturic calcium oxalate nephrolithiasis, and uric acid lithiasis with or without calcium stones.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Used in combination to treat Acidosis, renal tubular Combination Product in combination with: Citric acid (DB04272), Sodium citrate (DB09154) ••• ••• ••••• Used in combination for therapy Bowel preparation therapy Combination Product in combination with: Potassium bicarbonate (DB11098) •••••••••••• •••••••• •••••••••••• Used in combination to treat Constipation Combination Product in combination with: Potassium bicarbonate (DB11098) •••••••••••• •••••••• •••••••••••• Treatment of Hypocitraturic calcium oxalate nephrolithiasis •••••••••••• Management of Hypocitraturic calcium oxalate nephrolithiasis •••••••••••• - Associated Therapies
- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Potassium citrate induces changes in the urine which renders urine less susceptible to the formation of crystals and stones from salts e.g. calcium oxalate, calcium phosphate and uric acid. Increased citrate levels in the urine will make complexation with calcium which decrease the calcium ion activity and decrease the chance for the formation of calcium phosphate crystals. Citrate also inhibits the spontaneous nucleation of calcium oxalate and calcium phosphate.
- Mechanism of action
After oral administration of potassium citrate, its metabolism yields alkaline load. Potassium Citrate therapy appears to increase urinary citrate mainly by modifying the renal handling of citrate, rather than by increasing the filtered load of citrate. In addition to raising urinary pH and citrate, Potassium Citrate increases urinary potassium by approximately the amount contained in the medication. In some patients, Potassium Citrate causes a transient reduction in urinary calcium.
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
Potassium Citrate is absorbed and the citrate is metabolised to bicarbonate.
- Route of elimination
Urinary; less than 5% unchanged.
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
LD50 (dog): Intravenous 176 mg/kg.
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbacavir Potassium citrate may increase the excretion rate of Abacavir which could result in a lower serum level and potentially a reduction in efficacy. Acebutolol Potassium citrate may increase the hyperkalemic activities of Acebutolol. Aceclofenac Potassium citrate may increase the hyperkalemic activities of Aceclofenac. Acemetacin The therapeutic efficacy of Potassium citrate can be decreased when used in combination with Acemetacin. Acetaminophen Potassium citrate may increase the excretion rate of Acetaminophen which could result in a lower serum level and potentially a reduction in efficacy. - Food Interactions
- Take with food. Take potassium citrate within 30 minutes of eating to limit gastrointestinal irritation.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Potassium citrate monohydrate EE90ONI6FF 6100-05-6 PJAHUDTUZRZBKM-UHFFFAOYSA-K - Active Moieties
Name Kind UNII CAS InChI Key Potassium cation ionic 295O53K152 24203-36-9 NPYPAHLBTDXSSS-UHFFFAOYSA-N Citric acid unknown XF417D3PSL 77-92-9 KRKNYBCHXYNGOX-UHFFFAOYSA-N - Product Images
- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Polycitra-K Solution 398 mg / 5 mL Oral Janssen Pharmaceuticals 1996-12-31 2009-10-02 Canada 
Polycitra-K Powder 1.193 g / 4.5 g Oral Alza 1996-12-31 2001-08-01 Canada Potassium Citrate Tablet 10 meq/1 Oral Upsher-Smith Laboratories, LLC 2006-09-01 Not applicable US 
Potassium Citrate Tablet 5 meq/1 Oral Upsher-Smith Laboratories, LLC 2006-09-01 Not applicable US 
Urocit-K Tablet, extended release 15 meq/1 Oral Physicians Total Care, Inc. 2010-09-15 Not applicable US 
- Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Potassium Citrate Tablet, extended release 10 meq/1 Oral AvKARE 2020-11-18 Not applicable US Potassium Citrate Tablet, extended release 5 meq/1 Oral bryant ranch prepack 2021-02-15 Not applicable US Potassium Citrate Tablet, extended release 10 meq/1 Oral ANI Pharmaceuticals, Inc. 2020-03-16 Not applicable US Potassium Citrate Tablet, extended release 540 mg/1 Oral Rising Pharmaceuticals, Inc. 2006-06-19 2011-02-03 US Potassium Citrate Tablet, extended release 15 meq/1 Oral Bionpharma Inc. 2019-12-14 Not applicable US - Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image CITRAL SYRUP (PLAIN) 500 mg/5 ml Syrup 500 mg/5ml Oral SINGAPORE PHARMACEUTICAL PRIVATE LIMITED 1991-09-16 Not applicable Singapore 
K Lyte Tab Lime & Orange Flav Tablet, effervescent 975 mg / tab Oral Bristol Labs Division Of Bristol Myers Squibb 1965-12-31 1997-08-14 Canada Potassium 99mg Tablets Tablet 99 mg / tab Oral Bioforce Canada Inc. 1994-12-31 1997-04-14 Canada Potassium Tab 99mg Tablet 99 mg / tab Oral Da Vinci Laboratories, Division Of Foodscience Corporation 1981-12-31 1997-05-08 Canada Prime's Mixture Potassium Citrate Syrup Oral PRIME PHARMACEUTICAL SDN. BHD. 2020-09-08 Not applicable Malaysia 
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image B 6 Plus Potassium citrate (50 mg) + Magnesium oxide (50 mg) + Niacin (20 mg) + Pyridoxine (50 mg) + Riboflavin (2.4 mg) + Thiamine (10 mg) Tablet Oral Anabolic Laboratories Inc. 1967-12-31 2004-03-15 Canada B6 Plus Tab Potassium citrate (50 mg) + Magnesium oxide (50 mg) + Niacin (20 mg) + Pyridoxine hydrochloride (50 mg) + Riboflavin (2.4 mg) + Thiamine (10 mg) Tablet Oral Vita Health Products Inc 1979-12-31 2002-08-01 Canada BIOCHETASI Potassium citrate (50 mg) + Citric acid (70 mg) + Cocarboxylase (50 mg) + Riboflavin 5'-phosphate sodium anhydrous (25 mg) + Pyridoxine hydrochloride (12.5 mg) + Sodium citrate (425 mg) Tablet, effervescent Oral Alfasigma s.p.a. 2014-07-08 Not applicable Italy 
BIOCHETASI Potassium citrate (1 mg) + Riboflavin-5'-phosphate sodium salt dihydrate (25 mg) + Pyridoxine hydrochloride (15 mg) + Sodium citrate (49 mg/3ml) + Thiamine (25 mg) Injection, powder, for solution Intramuscular Alfasigma s.p.a. 2014-07-08 2023-03-30 Italy BIOCHETASI Potassium citrate (10 mg) + Cocarboxylase (150 mg) + Riboflavin-5'-phosphate sodium salt dihydrate (50 mg) + Pyridoxine hydrochloride (30 mg) + Sodium citrate (250 mg) Suppository Rectal Alfasigma s.p.a. 2014-07-08 Not applicable Italy - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Cytra 3 Potassium citrate monohydrate (550 mg/5mL) + Citric acid monohydrate (334 mg/5mL) + Sodium citrate (500 mg/5mL) Syrup Oral Pegasus Laboratories 2006-05-05 2009-10-17 US Cytra 3 Potassium citrate monohydrate (550 mg/5mL) + Citric acid monohydrate (334 mg/5mL) + Sodium citrate (500 mg/5mL) Syrup Oral Cypress Pharmaceuticals, Inc. 2008-07-29 2014-10-11 US Cytra-K Potassium citrate monohydrate (1100 mg/5mL) + Citric acid monohydrate (334 mg/5mL) Solution Oral Cypress Pharmaceuticals, Inc. 2008-09-30 2014-10-11 US Cytra-K Crystals Potassium citrate monohydrate (3.3 g/1) + Citric acid monohydrate (1.002 g/1) Granule, for solution Oral Cypress Pharmaceuticals, Inc. 2003-05-01 Not applicable US Lab 52 Essential Oil Sensitive Potassium citrate monohydrate (5.53 g/100g) + Sodium fluoride (0.32 g/100g) Paste, dentifrice Dental TOOTHFILM INC 2022-05-07 Not applicable US
Categories
- ATC Codes
- A12BA02 — Potassium citrate
- Drug Categories
- Acids, Acyclic
- Agents causing hyperkalemia
- Alimentary Tract and Metabolism
- Alkalinizing Activity
- Calculi Dissolution Agent
- Citrates
- Citric Acid Derivatives
- Diuretics
- Expectorants
- Metabolic Alkalinizer
- Mineral Supplements
- Minerals
- Natriuretic Agents
- Potassium Salt
- Replacement Preparations
- Respiratory System Agents
- Tricarboxylic Acids
- Urinary Alkalinisers
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as tricarboxylic acids and derivatives. These are carboxylic acids containing exactly three carboxyl groups.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Carboxylic acids and derivatives
- Sub Class
- Tricarboxylic acids and derivatives
- Direct Parent
- Tricarboxylic acids and derivatives
- Alternative Parents
- Tertiary alcohols / Carboxylic acid salts / Carboxylic acids / Organic potassium salts / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
- Substituents
- Alcohol / Aliphatic acyclic compound / Carbonyl group / Carboxylic acid / Carboxylic acid salt / Hydrocarbon derivative / Organic alkali metal salt / Organic oxide / Organic oxygen compound / Organic potassium salt
- Molecular Framework
- Aliphatic acyclic compounds
- External Descriptors
- potassium salt (CHEBI:64733)
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- 86R1NVR0HW
- CAS number
- 866-84-2
- InChI Key
- QEEAPRPFLLJWCF-UHFFFAOYSA-K
- InChI
- InChI=1S/C6H8O7.3K/c7-3(8)1-6(13,5(11)12)2-4(9)10;;;/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);;;/q;3*+1/p-3
- IUPAC Name
- tripotassium 2-hydroxypropane-1,2,3-tricarboxylate
- SMILES
- [K+].[K+].[K+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O
References
- General References
- External Links
- PubChem Compound
- 13344
- PubChem Substance
- 310265041
- ChemSpider
- 12775
- 54993
- ChEBI
- 64733
- ChEMBL
- CHEMBL1200458
- Wikipedia
- Potassium_citrate
- FDA label
- Download (81.6 KB)
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample dataNot Available Completed Treatment Gastroenteritis 1 somestatus stop reason just information to hide Not Available Recruiting Not Available Congenital Mitral Insufficiency 2 somestatus stop reason just information to hide Not Available Recruiting Not Available COVID-19, Long Haul / Long Haul COVID / Post-Acute COVID-19 / Post-acute COVID-19 (PACS), or "Long COVID" Syndrome 1 somestatus stop reason just information to hide Not Available Recruiting Not Available Heart Failure Congenital 1 somestatus stop reason just information to hide Not Available Recruiting Treatment Kidney Stones 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Tablet Oral Injection, powder, for solution Intramuscular Injection, solution Intramuscular Suppository Rectal Capsule Oral Syrup Oral 500 mg/5ml Granule, for solution Oral Tablet, film coated Powder Oral Tablet, effervescent Oral 975 mg / tab Powder, for solution Oral Granule Oral 2157.3 mg Syrup Oral Tablet Oral Paste, dentifrice Dental Aerosol Dental Liquid Oral Solution Oral Granule, effervescent Oral Powder Oral 1.193 g / 4.5 g Solution Oral 398 mg / 5 mL Tablet, effervescent Oral Tablet Oral 99 mg / tab Tablet Oral 15 meq/1 Tablet Oral 5 meq/1 Tablet, extended release Oral 10 meq/1 Tablet, extended release Oral 1080 mg/1 Tablet, extended release Oral 15 meq/1 Tablet, extended release Oral 5 meq/1 Tablet, extended release Oral 540 mg/1 Tablet Oral 10 meq/1 Solution Oral 5 % w/v For solution Oral Solution Oral 200 mg/5ml Syrup Oral 3 g/10ml Syrup Oral Tablet, extended release Oral 1080 mg Tablet, extended release Oral 540 mg Tablet, extended release Oral Tablet Oral 540 mg Tablet, extended release Oral 108000000 mg Syrup Solution Nasal Tablet Oral 1080 mg Tablet - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 39.4 mg/mL ALOGPS logP -0.7 ALOGPS logP -1.3 Chemaxon logS -0.89 ALOGPS pKa (Strongest Acidic) 3.05 Chemaxon pKa (Strongest Basic) -4.2 Chemaxon Physiological Charge -3 Chemaxon Hydrogen Acceptor Count 7 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 140.62 Å2 Chemaxon Rotatable Bond Count 5 Chemaxon Refractivity 68.14 m3·mol-1 Chemaxon Polarizability 14.23 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS splash10-0a4i-0009000000-1c9c5a3c5c210234aa14 - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 127.92728 predictedDeepCCS 1.0 (2019) [M+H]+ 130.01086 predictedDeepCCS 1.0 (2019) [M+Na]+ 135.92238 predictedDeepCCS 1.0 (2019)
Drug created at September 23, 2015 16:41 / Updated at October 14, 2024 05:53